Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (5362)	9/21/1998 5:01:00 PM
From: Robert L. Ray	Respond to of 6136

AGPH made a Bloomberg market mover list today. home.snap.com Agouron Pharmaceuticals Inc. (AGPH) rose as much as 3 3/4 to 35 1/4 as the developer of drugs to treat HIV was raised to ''buy'' from ''outperform'' by Lehman Brothers Inc. Eric Ende, who co-authored a report with analyst C. Anthony Butler. They raised their earnings estimate for fiscal 1999 ending in June to $1.33 a share from 94 cents, reflecting quicker penetration and greater market share for Agouron's AIDS drug Viracept. Ende said Agouron will benefit from last week's news that Merck & Co. (MRK) stopped the twice-daily dosage trials for its AIDS drug Crixivan, and from Abbott Laboratories (ABT)'s manufacturing problems with its Norvir.

To: Steve Fancy who wrote (5362)	9/21/1998 6:04:00 PM
From: Tom DuBois	Respond to of 6136

YAHOO has earnings consensus at .22 but the WHISPER at .03!! Can this be right?? Tom

To: Steve Fancy who wrote (5362)	9/21/1998 6:15:00 PM
From: Izzy	Read Replies (1) \| Respond to of 6136

OK all you stock market gurus. Why did we sell last week? Are you going to start buying again now? IMNR closed at 12 1/4 (+ 1 23/32) and VRTX closed at 23 3/4 (+ 1 5/16); all three stocks (AGPH, IMNR, VRTX) are now above their 200 day moving average. And a good part of my AGPH/IMNR shares was called away a few wks ago by margin call (I had the right idea). AND, I am not whining! I just knew I had made good stock choices and now we're off to the races (it's OK; I still have enough shares to make some big money). BTW, aren't you guys using a discount broker? I transferred my acc't away from the big broker house, who was making more money than I was.

To: Steve Fancy who wrote (5362)	9/21/1998 6:19:00 PM
From: billkirn	Respond to of 6136

The wind is firmly at our backs. So much encouraging news that seems to indicate a long and prosperous life for Viracept. Over the last month, information from many fronts has reduced the risk and increased the earnings prospects for Agouron. Finally the overwhelming evidence supports Viracept as the major component in AIDS treatment. It works in almost all combinations and hopefully with Sustiva (1 dose), Viracept (2 dose) per day and a favorable combo resistance and side stuff profiles could replace Crix completely over the next few years. Only good news for awhile, isn't this nice! Bill